Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2020-04-16 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2019年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the 2019 Annual General Meeting (AGM) of 特一药业集团股份有限公司. It details the procedures of convening and holding the AGM, the qualifications of attendees and convener, the voting procedures, and the voting results for various resolutions including the 2019 annual report and financial statements. The document is focused on the AGM event and its legal compliance, not the annual report itself or financial statements. It is not a report publication announcement but a legal opinion on the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (6017 characters) and content confirm it is a substantive legal opinion on the AGM, not a brief announcement or certification.
2020-04-16 Chinese
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2019 Annual General Meeting (AGM) resolution announcement for 特一药业集团股份有限公司. It details the meeting date, voting methods, attendance, and voting results on various proposals including the 2019 annual report, financial statements, profit distribution, and other corporate matters. The document does not contain the full annual report or financial statements themselves but rather the official voting results and resolutions passed at the AGM. The length is about 5,048 characters, which is consistent with a detailed announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-04-16 Chinese
2020年非公开发行股票募集资金使用可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票募集资金使用可行性分析报告" which translates to "Non-public Issuance of Shares Fundraising Feasibility Analysis Report." It details the use of funds raised from a non-public stock issuance, including investment plans, project descriptions, economic benefit analyses, and timelines. The content focuses on the feasibility and planned use of capital raised through a private placement of shares, including detailed investment projects and their expected returns. This is a capital/financing update document, providing information on fundraising activities and the intended use of proceeds. It is not an annual report, earnings release, or other financial statement, nor is it a regulatory announcement or proxy material. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement of a report.
2020-04-07 Chinese
关于前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the usage of previously raised funds by 特一药业集团股份有限公司. It references regulatory requirements from the China Securities Regulatory Commission (CSRC) and details the amount, management, and actual use of funds raised through a convertible bond issuance. The document includes detailed financial figures on the raised funds, their allocation, and usage status as of December 31, 2019. It also includes attachments with detailed tables comparing committed and actual investment amounts and project benefits. The content focuses on the use of previously raised capital rather than presenting a full annual or interim financial report, earnings release, or management discussion. It is a specialized report on the use of capital raised, which aligns with the category of Capital/Financing Update (CAP). The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best fitting classification is CAP with high confidence.
2020-04-07 Chinese
未来三年（2020-2022年）股东分红回报规划
Notice of Dividend Amount Classification · 85% confidence The document is a detailed plan outlining the company's shareholder dividend return policy for the years 2020-2022. It discusses profit distribution principles, forms, timing, conditions, decision-making mechanisms, and adjustment procedures. It is not a financial report with actual financial statements or results, nor is it an announcement of voting results or a regulatory filing. Instead, it is a policy document related to dividend distribution planning. This fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend policy and shareholder returns over a multi-year period.
2020-04-07 Chinese
独立董事关于第四届董事会第十一次会议审议事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on matters related to a non-public issuance of A-shares by the company, including the legality, feasibility, and use of raised funds. It references compliance with laws and regulations, board meeting procedures, and submission of proposals to the shareholders' meeting. The content is focused on governance and regulatory compliance related to capital raising activities, but it is not a full financial report or earnings release. The document is relatively short (1968 characters) and serves as an official opinion or statement rather than a detailed report. It does not contain financial statements or detailed financial analysis. This type of document fits best under Regulatory Filings (RNS), as it is a formal regulatory disclosure related to corporate governance and capital raising but not a full report or announcement of voting results.
2020-04-07 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.